Related Experiment Video
Updated: Aug 4, 2026
An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse
Published on: April 7, 2014
Inhibition of inflammatory corneal angiogenesis by TNP-470
A M Joussen1, W D Beecken, Y Moromizato
1Department of Vitreoretinal Surgery, Center for Ophthalmology, University of Cologne, Köln, Germany. joussena@aol.com
Purpose:
To determine the efficacy of the angiogenic inhibitor TNP-470 on inflammatory corneal neovascularization. Topical and systemic delivery of the drug were investigated in a murine model as well as inhibition of endothelial cell proliferation in vitro and in vivo.
Methods:
The effect of TNP-470 on VEGF- and bFGF-stimulated bovine capillary endothelial (BCE) cell proliferation was evaluated in vitro. Corneal neovascularization was induced in vivo by mechanical debridement of the corneal and limbal epithelium with 0.15 M NaOH on C57BL6 mice. TNP-470 was administered systemically at 30 mg/kg body weight (BW) every other day or topically three times daily in a concentration of 5 ng/ml dissolved in methylcellulose. Vessel length was investigated on day 7. VEGF protein content in murine corneas was analyzed by ELISA on days 2, 4, and 7 of treatment. A modified bromouridine (BrdU) ELISA was used to quantify endothelial cell proliferation.
Results:
TNP-470 exerted a dose-dependent inhibition of bFGF- and VEGF-induced endothelial cell proliferation in vitro. Both systemic and topical application of TNP-470 led to a significant reduction of inflammatory corneal neovascularization (P < 1 x 10(-5)). BrdU labeling showed that TNP-470 inhibited endothelial cell proliferation. VEGF protein levels were reduced by systemic TNP-470 treatment.
Conclusions:
These results suggest that TNP-470 reduces inflammatory corneal angiogenesis by directly inhibiting endothelial cell proliferation. Topical and systemic treatment with TNP-470 reduces VEGF levels that are responsible for vessel growth during the neovascularization process.
Insights
The angiogenic inhibitor TNP-470 effectively reduces inflammatory corneal neovascularization by inhibiting endothelial cell proliferation. Both topical and systemic TNP-470 treatments lower VEGF levels, crucial for new blood vessel growth.
Area of Science:
- Ophthalmology
- Vascular Biology
- Pharmacology
Background:
- Inflammatory corneal neovascularization poses a significant threat to vision.
- Angiogenesis, the formation of new blood vessels, plays a critical role in this process.
- Inhibiting angiogenesis is a key therapeutic strategy for managing corneal neovascularization.
Purpose of the Study:
- To evaluate the efficacy of TNP-470, an angiogenic inhibitor, in treating inflammatory corneal neovascularization.
- To investigate both topical and systemic delivery methods of TNP-470.
- To assess the drug's impact on endothelial cell proliferation in vitro and in vivo.
Main Methods:
- Assessed TNP-470's effect on bovine capillary endothelial (BCE) cell proliferation stimulated by VEGF and bFGF in vitro.
- Induced corneal neovascularization in a murine model using mechanical debridement and NaOH.
- Administered TNP-470 systemically (30 mg/kg BW every other day) or topically (5 ng/ml three times daily) and analyzed vessel length, VEGF protein content, and endothelial cell proliferation (BrdU labeling) on day 7.
Main Results:
- TNP-470 demonstrated dose-dependent inhibition of endothelial cell proliferation in vitro.
- Both systemic and topical TNP-470 significantly reduced inflammatory corneal neovascularization (P < 1 x 10(-5)).
- TNP-470 inhibited endothelial cell proliferation in vivo, and systemic treatment reduced VEGF protein levels.
Conclusions:
- TNP-470 effectively reduces inflammatory corneal angiogenesis by directly inhibiting endothelial cell proliferation.
- Both topical and systemic TNP-470 treatments decrease VEGF levels, thereby limiting neovascularization.
- TNP-470 shows promise as a therapeutic agent for inflammatory corneal neovascularization.
